Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 3% Dividend Yields

During times of turbulence and uncertainty in the markets, even when markets are at all-time highs, many investors turn to dividend-yielding stocks.

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy.

Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.

Gilead Sciences, Inc. GILD

Dividend Yield: 4.00%
Cantor Fitzgerald analyst Olivia Brayer maintained a Neutral rating and cut the price target from $75 to $70 on July 22. This analyst has an accuracy rate of 65%.
RBC Capital analyst Brian Abrahams reiterated a Sector Perform rating with a price target of $74 on July 1. This analyst has an accuracy rate of 69%.
Recent News: On July 25, Gilead Sciences announced new 5-year data reinforcing Biktarvy as a long term HIV treatment.
Benzinga Pro's real-time newsfeed alerted to latest GILD news

Pfizer Inc. PFE

Dividend Yield: 5.46%
Barclays analyst Carter Gould maintained an Equal-Weight rating and raised the price target from $28 to $30 on July 10. This analyst has an accuracy rate of 64%.
Argus Research analyst David Toung downgraded the stock from Buy to Hold on March 22. This analyst has an accuracy rate of 68%.
Recent News: Pfizer announced last week that the European Commission approved a conditional marketing authorization for DURVEQTIX, a gene therapy for severe and moderately severe hemophilia B in adults whom meet certain criteria.
Benzinga Pro's charting tool helped identify the trend in PFE's stock.

Bristol-Myers Squibb Company BMY

Dividend Yield: 4.76%
Deutsche Bank analyst James Shin maintained a Hold rating and cut the price target from $53 to $45 on July 23. This analyst has an accuracy rate of 73%.
Wells Fargo analyst Mohit Bansal maintained an Equal-Weight rating and raised the price target from $51 to $52 on April 18. This analyst has an accuracy rate of 77%.
Recent News: On July 26, Bristol-Myers Squibb posted better-than-expected quarterly earnings.
Benzinga Pro's signals feature notified of a potential breakout in BMY shares.